Almac wins Laboratory Team of the Year at The Irish Laboratory Awards 2013
Almac‘s Enzyme Research and Development team have been recognised at The Irish Laboratory Awards by winning “Laboratory Team of the Year.”
The awards, the first of their kind in Ireland, were held to recognise the success and achievements of Ireland’s internationally renowned scientists in areas including innovation, leadership and collaboration, and focus on the on-going work of Irish scientists to grow and develop sustainable, globally competitive science research.
The 30-strong Almac Biocatalysis Team has been at the forefront of innovation and solutions to a large number of pharmaceutical companies and API manufacturers across the world. Enzymatic technology is increasingly displacing chemical processes, yielding a higher quality product at a more attractive price while making significant benefit to the environment.
Tom Moody, Head of Biocatalysis and Isotope Chemistry at Almac commented, “Our team is recognised globally as a key player in the area of biocatalyst research and development and we are delighted to have won this award.”
“It is now acknowledged that the need for green, economic, robust and scalable processes is at the forefront of customer research plans for the synthesis of chiral APIs and intermediates. This award demonstrates our continued success in this field, and the Enzyme Research and Development team is a key to our future.”
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.